Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2018, Vol. 23 ›› Issue (10): 1153-1158.doi: 10.12092/j.issn.1009-2501.2018.10.011

Previous Articles     Next Articles

Effects of fasudil combined with rosuvastatin in the treatment of vascular dementia on patients' cognitive function, C-reactive protein and oxidative stress

CHEN Juanyan 1,2, SONG Shuijiang 1, XU Dongjuan 2, XU Qiong 2, LI Hongfei 2   

  1. 1 Department of Neurology, the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou 310009, Zhejiang, China; 2 Department of Neurology, Dongyang People's Hospital, Dongyang 322100, Zhejiang, China
  • Received:2018-04-25 Revised:2018-06-24 Online:2018-10-26 Published:2018-10-25

Abstract:

AIM: To investigate the effects of fasudil combined with rosuvastatin in the treatment of vascular dementia (VD) on patients' cognitive function, C-reactive protein and oxidative stress.  METHODS: One hundred and eighty-four VD patients were selected as study subjects. They were divided into the rosuvastatin group and the combined drug group (fasudil + rosuvastatin) according to the random number table method. Each group contains 92 cases. MMSE (Mini-Mental State Examination), MoCA (Montreal Cognitive Assessment) and ADL (Activities of Daily Living) scores, the level of CRP (C-reactive protein), MDA (malondialdehyde), Hcy (serum homocysteine) and SOD (superoxide dismutase), as well as blood lipid index (TC, TG, LDL-C, HDL-C) levels, clinical efficacy and incidence of adverse reaction were compared between the two groups before and after treatment. RESULTS:The total effective rate of the combined drug group (93.48%) was significantly higher than that of the rosuvastatin group (82.61%), and the difference was statistically significant (P<0.05). After treatment, the MMSE, MoCA and ADL scores of the combined drug group were significantly higher than that of the rosuvastatin group, while the level of CRP, MDA, Hcy, TC, TG and LDL-C was significantly lower than that of the rosuvastatin group, and the SOD level was significantly higher than that of the rosuvastatin group, which were of statistically significant difference (P<0.05). There was no significant difference in the incidence of adverse reaction (P>0.05). CONCLUSION: Fasudil combined with rosuvastatin in the treatment of VD can improve patients' cognitive function and daily living ability, reduce oxidative stress response and the level of C-reactive protein, and improve patients' blood lipid index. This method is of significant clinical efficacy and high safety.

Key words: vascular dementia, fasudil, rosuvastatin, cognitive function, C-reactive protein, oxidative stress

CLC Number: